Information for patients
EnglishA simple urine test can relieve the burden of frequent cystoscopies
The current standard procedure for follow-up of non-muscle-invasive bladder cancer (NMIBC) is cystoscopy combined with cytology to detect tumour cells. In general, these procedures are scheduled frequently in the beginning and only reduced in frequency over time if the tumour does not recur. Cystoscopy is an invasive procedure often causing pain and discomfort during and after the procedure.
Bladder cancer biomarkers are detected in simple urine tests, meaning your next follow-up cystoscopy can be delayed. Learn how urinary biomarkers can positively impact on your future check-ups!
Urine biomarkers are indicators of tumour recurrence
Detected via a somple urine test instead of by an invasive procedure
A quick and easy way to find out whether your cancer has come back
With a negative test result there is very high certainty that no high-risk bladder cancer tumour was missed
Bladder EpiCheck® is included in the European guidelines, which state that Bladder EpiCheck® has such high sensitivity and negative predictive value for high-grade disease, that it can be used in the initial diagnostic workup to avoid/implement cystoscopy, or in follow-up to replace or postpone cystoscopy [1].
Bladder EpiCheck® is a highly sensitive and specific biomarker test, which ensures that a negative (favourable) test result accurately rules out high-risk tumours with 99% certainty [2,3].
The reliable outcomes of this biomarker test would allow your physician to safely reduce the number of cystoscopies, in favour of a simple urinary test.
How to access the test?
You can bring this brochure to any urologist. By booking in for a consultation, you can discuss any concerns you have regarding your current followup schedule.
The urologist can contact the distributor of Bladder EpiCheck® in your county to organise a test for you.
How to acces the test?
You can bring this brochure to any urologist. By booking in for a consultation, you can discuss any concerns you have regarding your current followup schedule.
The urologist can contact the distributor of Bladder EpiCheck® in your county to organise a test for you.
Distributor by country:
References:
- Gontero P, Birtle A, Compérat E, et al. EAU guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and CIS). Update April 2024.
- Laukhtina E, Shim SR, Mori K, et al. Eur Urol Oncol 2021;4:927-42.
- Laukhtina E, Shim SR, Mori K, et al. Eur Urol Oncol 2022;5:480-1.
© 2020 BCaMonitor (date of release May 2020 – Updated April 2024)